August 11, 2022
Abstract Objective To characterize diet quality across a global cohort of people with HIV (PWH). Design Cross-sectional analysis. Methods Leveraging REPRIEVE data from baseline across five Global Burden […]
June 3, 2022
Abstract Background People with HIV (PWH) have subclinical coronary artery disease (CAD) despite low traditional atherosclerotic cardiovascular disease (ASCVD) risk scores. Coronary plaque in PWH presents […]
June 3, 2022
Abstract Background Limited data are available regarding asymptomatic COVID-19 among people with HIV (PWH). Data on a representative subset of PWH enrolled in REPRIEVE, a global clinical trial […]
March 7, 2022
Abstract Background We sought to explore multinational differences in functional status by Global Burden of Disease (GBD) regions in the REPRIEVE cohort. Methods REPRIEVE is a […]
March 3, 2022
Abstract Background Among ART-treated people with HIV (PWH), persistent systemic immune activation contributes to atherogenesis, cardiovascular disease (CVD) events, and mortality. Factors associated with key immune […]
December 13, 2021
Abstract Background People with HIV (PWH) are at increased risk for cardiovasvular disease (CVD) and sudden cardiac death. Prior work has suggested an association between HIV […]
December 13, 2021
Abstract Little is known regarding COVID-19 vaccination rates in people with HIV (PWH), a vulnerable population with significant morbidity from COVID-19. We assessed COVID-19 vaccination rates […]
December 13, 2021
Abstract Background Emerging data demonstrate that the use of integrase inhibitor (INSTI)-based antiretroviral treatment (ART) is associated with increased weight, but the cardiometabolic health consequences of […]
July 7, 2021
Abstract Background In addition to traditional cardiovascular (CV) risk factors, antiretroviral therapy, lifestyle, and HIV-related factors may contribute to future CV events in persons with HIV […]
July 7, 2021
Key Points Question What is the extent of coronary artery disease among people with well-controlled HIV and low to moderate risk of atherosclerotic cardiovascular disease (ASCVD), and […]
September 17, 2020
The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is the largest study of cardiovascular disease in human immunodeficiency virus. Enrolling 7770 participants from 2015 […]
September 17, 2020
Background: Patterns of antiretroviral therapy (ART) use and immunologic correlates vary globally, and contemporary trends are not well described. Methods: The REPRIEVE trial (Randomized Trial to […]
September 17, 2020
Background: Reproductive aging may contribute to cardiometabolic comorbid conditions. We integrated data on gynecologic history with levels of an ovarian reserve marker (anti-müllerian hormone [AMH)] to […]
September 17, 2020
Abstract: Because persons who identify across the transgender spectrum (PATS) are a key population in human immunodeficiency virus (HIV) yet are under-reported in HIV and cardiovascular […]
September 17, 2020
Background: Chronic kidney disease is a common comorbid condition among persons living with human immunodeficiency virus (PWH). We characterized baseline kidney function in the REPRIEVE (Randomized […]
September 17, 2020
Background: People with human immunodeficiency virus (PWH) are at risk for accelerated development of physical function impairment and frailty; both associated with increased risk of falls, […]
September 17, 2020
Background: People with human immunodeficiency virus (PWH) face increased risks for heart failure and adverse heart failure outcomes. Myocardial steatosis predisposes to diastolic dysfunction, a heart […]
September 17, 2020
Background: The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) is a multicenter, randomized, placebo-controlled trial, designed to test whether a statin medication can prevent […]
September 17, 2020
Background: Cardiovascular disease (CVD) is more frequent among people with HIV (PWH) and may relate to traditional and nontraditional factors, including inflammation and immune activation. A critical need […]
September 17, 2020
Background: The REPRIEVE Mechanistic Substudy (A5333s) represents the first large, randomized, CCTA-based assessment of the effects of a primary prevention strategy for CVD on high-risk CAD, […]